Cutaneous Oncology News

Factors such as age, tumor size and immunosuppression are linked with survival outcomes in localized adnexal carcinomas, according to a study.

DermTech has filed for voluntary chapter 11 protection in the U.S. Bankruptcy Court for the District of Delaware, the company announced in a press release.

Suntegrity Skincare has issued a voluntary recall of nine Impeccable Skin Sunscreen Foundation lots, according to a press release from the FDA.

CHICAGO — Combining an mRNA-based cancer vaccine with standard-of-care pembrolizumab significantly improved RFS and distant metastasis-free survival among patients with resected high-risk melanoma, study results showed.

The FDA has approved the expanded use area of Klisyri to up to 100 cm2 on the face and scalp for the treatment of actinic keratosis, Almirall announced in a press release.

New evidence suggests that a novel, benign nail finding may facilitate the detection of BRCA1-associated protein tumor predisposition syndrome which leaves patients at risk for certain cancers, according to a study.

The FDA has granted breakthrough device designation to VIO Skin Platform, an AI-powered tool that evaluates suspicious lesions for skin cancer, Enspectra Health announced in a press release.

CHICAGO — A front-line treatment regimen including lifileucel and pembrolizumab produced ongoing durable responses in some patients with unresectable or metastatic melanoma, according to findings presented at ASCO Annual Meeting.

CHICAGO — Sequencing encorafenib plus binimetinib with nivolumab and ipilimumab did not delay disease progression in adults with advanced BRAF-mutated melanoma, results from a randomized phase 2 trial showed.

CHICAGO — Adjuvant dabrafenib plus trametinib reduced mortality risk for adults with resected stage III BRAF V600-mutant melanoma, according to final results of the randomized phase 3 COMBI-AD trial.